ERAS
vs
S&P 500
ERAS
S&P 500
Over the past 12 months, ERAS has significantly outperformed S&P 500, delivering a return of +694% compared to the S&P 500's +12% growth.
Stocks Performance
ERAS vs S&P 500
Performance Gap
ERAS vs S&P 500
Performance By Year
ERAS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Erasca Inc
Glance View
Erasca, Inc. is a clinical stage precision oncology company that focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. The company is headquartered in San Diego, California and currently employs 123 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm is engaged in oncology and RAS targeting to create therapies and combination regimens for the treatment of cancer. Its product candidates are ERAS-007 and ERAS-601, which together comprises its MAPKlamp. In addition, it also includes two discovery programs, ERAS-9 and ERAS-11, small molecule inhibitor programs targeting SOS1 and MYC, respectively. Its MAPKlamp is an approach targeting upstream and downstream nodes in the RAS/MAPK pathway designed to shut down, or clamp, the signaling of various oncogenic drivers, such as RTKs, NF1, RAS, RAF, and MEK alterations trapped in between any nodes involving this pathway. With its MAPKlamp approach, it induces tumor regression in RAS/MAPK pathway-driven cancers, while also blocking the escape routes that lead to tumor resistance.
